Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support (ESSENTIAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04429334|
Recruitment Status : Completed
First Posted : June 12, 2020
Last Update Posted : May 3, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will be tested versus placebo.
All patients with a diagnosis of COVID-19, and a requirement for respiratory support will be considered for study participation. The applicable local requirements for informed consent will be followed. Where permissible, an emergency consent procedure will be followed for patients unable to provide consent by themselves. All potential study patients will receive standard of care treatment throughout the study. Patients will receive a continuous intravenous (i.v.) infusion of nangibotide at 1.0 mg/kg/h or a matching placebo. Treatment with study drug must be initiated as early as possible but no later than 48 hours after the initiation of ventilatory support (Patients will be treated for 5 days or until discharge from critical care, whichever is sooner). Follow-up visits will be performed on days 8 and 14. The end of study visit is at day 28. A further follow up visit will be undertaken on day 60.
|Condition or disease||Intervention/treatment||Phase|
|COVID19||Drug: nangibotide Drug: placebo||Phase 2|
ESSENTIAL was a randomized, double-blind, placebo-controlled trial, in which one dose of nangibotide was tested versus placebo. It took place in 14 sites in France and Belgium. The study was overseen by an independent Data Monitoring Committee (DMC).
The study was divided into two parts running sequentially without unblinding. Part 1 evaluated safety and tolerability study and included 60 patients, randomized in a 2:1 ratio of nangibotide to placebo. Part 2 included all recruited patients with an initially planned sample size of 370 patients, randomized in a 1:1 ratio of nangibotide to placebo.
All patients or their legally authorised representatives provided written informed consent or, in relevant countries, an independent physician, confirmed patient eligibility for enrolment in the trial.
Patients received a continuous intravenous infusion of nangibotide at 1.0 mg/kg/h or a matching placebo for 5 days (or until discharge from ICU, whichever was sooner). The treatment was in addition to standard of care.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||220 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features|
|Actual Study Start Date :||September 23, 2020|
|Actual Primary Completion Date :||May 20, 2022|
|Actual Study Completion Date :||June 22, 2022|
Continuous infusion of experimental agent for up to 120 hours
nangibotide 1.0 mg/kg/h
Placebo Comparator: placebo
Continuous infusion of matched placebo for up to 120 hours
- Incidence of adverse events until day 28 [ Time Frame: 28 days ]Part 1
- Clinical Status (7-point Ordinal Scale) assessed at Day 28 [ Time Frame: 28 days ]Part 2
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Provided informed consent (emergency consent according to local regulations where approved)
- Age 18 to 75 years (inclusive)
- Admitted to an intensive care unit
- Treatment with High Flow Nasal Oxygen, non-invasive ventilation or invasive mechanical ventilation for acute respiratory failure caused by COVID-19 for less than 48 hours
- A PaO2:FiO2 ratio of <200mmHg (<26.7kPa) with a FiO2 ≥0.6
- Confirmed laboratory diagnosis of COVID-19 within 7 days of meeting screening criteria
- Known pregnancy (positive urine or serum pregnancy test)
- Ongoing treatment with an immunomodulatory agent not included in the standard of care for COVID-19 (including participation in clinical trials of such agents)".
- Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg
- Anticipated transfer to another hospital, which is not a study site within 72 hours
- Expected to die within 6 months of treatment due to underlying chronic disease
Limitations of care in place during current hospital admission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04429334
|Study Chair:||Jean-Jacques Garaud, MD||INOTREM SA|
|Other Study ID Numbers:||
|First Posted:||June 12, 2020 Key Record Dates|
|Last Update Posted:||May 3, 2023|
|Last Verified:||May 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases